Dedicated to making the world safer

for those with food allergies!

HERSHEY, Pa. and ROCKVILLE, Md., Feb. 20, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc., ("ITI") a privately-held biotechnology company with laboratories in Rockville, MD, today announced the presentation of two posters at 2015 American Academy of Allergy, Asthma and Immunology meeting in Houston, Texas that support the company's proprietary lysosomal associated membrane protein (LAMP) vaccine program.Read More

LAMP Vaccine

The results of the Immune Tolerance Network’s (ITN) “Learning Early About Peanut” (LEAP), discussed on February 23, 2015 at the American Academy of Allergy, Asthma & Immunology Annual Meeting and published in the New England Journal of Medicine, demonstrate that consumption of a peanut-containing snack by infants who are at high-risk for developing peanut allergy prevents the subsequent development of allergy. The LEAP study, designed and conducted by the ITN with additional support from FARE and led by Professor Gideon Lack at Kings College London, is the first randomized trial to prevent food allergy in a large cohort of high-risk infants.

LEAP Study Around Food Allergy Prevention

 Patient in Kansas City -Desensitization Trial

Probiotic Lactobacillus Rhamnosus​

Oral immunotherapy (OIT) is a process in which the goal of the treatment is to desensitize patients by feeding them small incremental amounts of the food in which they are allergic to, making them less likely to react to the food allergen. While there has been encouraging results, there is still more that needs to be confirmed before this will be considered a long-term solution. Below are some links with additional information. please never try this at home or outside of a medical setting.


​New England Food Allergy Treatment Center Strict avoidance of peanuts and the constant fear of accidental exposure cause tremendous stress for children with peanut allergy and their families. As little as 1/44,000 of a peanut kernel can trigger a reaction for severely allergic individuals.

VIASKIN on The Horizon

Oral Immunotherapy - OIT

Food Allergy Treatments - Hope Is On The Horizon

While there is STILL NO CUREfor food allergies, there are a number of trial treatments which are showing promise. 

American Academy of Allergy, Asthma and immunology Landmark (AAAAI)  Study presented at AAAAI Annual Meeting paves way for food allergy prevention
LEAP study hints at new food allergy guidelines

​​Viaskin is a new trial that is based on a patch which administers the allergen directly on the skin. Once administered, the allergen is concentrated in the superficial layers of the skin, where it activates the immune system by specifically targeting antigen-presenting cells without passage of the antigen into the bloodstream. 
DBV calls this novel approach to immunotherapy as epicutaneous immunotherapy, or EPIT®. 
DBV Technologies believes EPIT® has the potential to provide all of the intended benefits of a disease-modifying treatment in allergy, while avoiding severe or life-threatening allergic reactions. 
​     Information taken directly from the Viaskin Technology Website
 

DBV Technologies

VIAskin peanut allergy patch in final trials in France, may be in US market 2018

Food Allergy Resources

Three studies under way at The Children’s Hospital of Philadelphia are looking at potential ways to desensitize children so that they can develop a level of tolerance to peanut protein that would provide some clinical protection against accidental exposure. Read More

​Three Peanut Immunotherapy Studies Underway​ Strict avoidance of peanuts and the constant fear of accidental exposure cause tremendous stress for children with peanut allergy and their families. As little as 1/44,000 of a peanut kernel can trigger a reaction for severely allergic individuals. Three studies under way at The Children’s Hospital of Philadelphia are looking at potential ways to desensitize children so that they can develop a level of tolerance to peanut protein that would provide some clinical protection against accidental exposure. Read More
​​The Lancet
The OIT Center - List of ArticlesType your paragraph here.

A strain of probiotic bacteria could offer a cure for potentially fatal peanut allergies, according to scientists in Australia. The breakthrough followed a trial in which a group of children were given increasing amounts of peanut flour, along with a probiotic called Lactobacillus rhamnosus, over an 18-month period. About 80 per cent of the children who had peanut allergies were subsequently able to tolerate peanuts. Read More